|
Placebo
|
navafenterol 50 μg
|
navafenterol 200 μg
|
navafenterol 400 μg
|
navafenterol 900 μg
|
navafenterol 1800 μg
|
navafenterol 2100 μg
|
Overall
|
---|
N
|
12
|
6
|
6
|
6
|
6
|
6
|
5
|
16
|
Any TEAE, n (%)
|
7 (58.3)
|
5 (83.3)
|
5 (83.3)
|
3 (50.0)
|
3 (50.0)
|
3 (50.0)
|
2 (40.0)
|
14 (87.5)
|
Most common TEAEs, n (%)a
|
Headache
|
3 (25.0)
|
3 (50.0)
|
1 (16.7)
|
2 (33.3)
|
2 (33.3)
|
1 (16.7)
|
0
|
10 (62.5)
|
Nasopharyngitis
|
1 (8.3)
|
3 (50.0)
|
1 (16.7)
|
0
|
0
|
0
|
2 (40.0)
|
7 (43.8)
|
Chest discomfort
|
1 (8.3)
|
1 (16.7)
|
1 (16.7)
|
0
|
0
|
0
|
0
|
3 (18.8)
|
Skin irritation
|
0
|
1 (16.7)
|
1 (16.7)
|
0
|
0
|
1 (16.7)
|
0
|
3 (18.8)
|
Wheezing
|
1 (8.3)
|
1 (16.7)
|
1 (16.7)
|
0
|
0
|
0
|
0
|
3 (18.8)
|
Cough
|
0
|
1 (16.7)
|
0
|
0
|
1 (16.7)
|
0
|
0
|
2 (12.5)
|
Dizziness
|
1 (8.3)
|
0
|
1 (16.7)
|
0
|
0
|
0
|
0
|
2 (12.5)
|
Feeling hot
|
0
|
1 (16.7)
|
0
|
0
|
0
|
0
|
1 (20.0)
|
2 (12.5)
|
Nausea
|
0
|
1 (16.7)
|
0
|
0
|
1 (16.7)
|
0
|
0
|
2 (12.5)
|
- TEAE treatment-emergent adverse event
- Adverse events were coded using Medical Dictionary for Regulatory Activities version 18.1
- aMost common TEAEs reported by ≥2 patients overall